Critical Review: FibroGen (NASDAQ:FGEN) vs. EOM Pharmaceutical (OTCMKTS:IMUC)

EOM Pharmaceutical (OTCMKTS:IMUC) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.

Profitability

This table compares EOM Pharmaceutical and FibroGen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EOM Pharmaceutical	N/A	N/A	N/A
FibroGen	2,598.55%	N/A	-26.27%

Institutional and Insider Ownership

72.7% of FibroGen shares are held by institutional investors. 3.3% of EOM Pharmaceutical shares are held by insiders. Comparatively, 2.0% of FibroGen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares EOM Pharmaceutical and FibroGen”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EOM Pharmaceutical	N/A	N/A	-$1.89 million	N/A	N/A
FibroGen	$29.62 million	1.22	-$47.58 million	$53.48	0.17

EOM Pharmaceutical has higher earnings, but lower revenue than FibroGen.

Risk & Volatility

EOM Pharmaceutical has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for EOM Pharmaceutical and FibroGen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EOM Pharmaceutical	0	0	0	0	0.00
FibroGen	1	1	1	0	2.00

FibroGen has a consensus target price of $43.00, indicating a potential upside of 381.52%. Given FibroGen’s stronger consensus rating and higher probable upside, analysts plainly believe FibroGen is more favorable than EOM Pharmaceutical.

Summary

FibroGen beats EOM Pharmaceutical on 7 of the 10 factors compared between the two stocks.

About EOM Pharmaceutical

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

About FibroGen

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.